Novel Hedgehog Inhibitor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul Frohna, MD, PhD, PharmD.

United statesSan diegoPaul frohnaAmerican thoracic societyInternational conferenceEndeavor biomedicinesNovel hedgehog inhibitorIncreases lung functionReduces lung fibrosisResults fromIdiopathic pulmonary fibrosisPlacebo controlled phase